We describe two sensory Guillain-Barre syndromes (GBS) after the ChAdOx1 vaccine.
•
We highlight the unique features of published GBS cases after the ChAdOx1 vaccine.
•
We propose a possible association between the vaccine and GBS.
•
To determine causality, data accumulation and epidemiologic analyses are mandatory.
Abstract
Massive vaccination against COVID-19 has become a global priority. Simultaneously, concerns regarding the safety of vaccines are growing. We describe two patients who developed sensory Guillain-Barre syndrome (GBS) shortly after the first dose of the ChAdOx1 vaccine. We also summarize 12 published cases of GBS after ChAdOx1 vaccination, highlighting their unique clinical and paraclinical features. We propose a possible association between the risk of GBS and the ChAdOx1 vaccine and recommend surveillance for GBS following vaccination. Population-based studies are needed to determine causality and whether specific subpopulations are susceptible.
